Breaking News Instant updates and real-time market news.

ANAB

AnaptysBio

$126.45

6.59 (5.50%)

08:26
02/19/18
02/19
08:26
02/19/18
08:26

AnaptysBio presents updated Phase 2 data for ANB020 in atopic dermatitis

AnaptysBio announced updated data from the company's Phase 2a trial of ANB020, its wholly-owned anti-IL-33 antibody program, in adult patients with moderate-to-severe atopic dermatitis. The Phase 2a proof-of-concept trial assessed ANB020 efficacy and safety in 12 moderate-to-severe adult atopic dermatitis patients. The primary efficacy objective of this study was to determine the percentage of patients achieving 50% improvement in their Eczema Area Severity Index score relative to enrollment baseline on day 29 post-ANB020 administration. Each patient was dosed with placebo 14 days following enrollment, and subsequently administered a single 300mg intravenous dose of ANB020 one week after placebo.Key observations included: ANB020 was efficacious in all 12 patients enrolled in this trial with each patient achieving at least EASI-50 on or before day 57 post-ANB020 administration; Rapid clinical response was observed by day 15 post-ANB020 administration with nine of 12 patients achieving EASI-50, of which three patients also achieved EASI score improvement of 75 percent relative to baseline; Day 29 results exceeded the primary efficacy objective of the trial with 10 of 12 patients achieving EASI-50, of which four patients also achieved EASI-75; Efficacy was sustained through day 140 following single dose administration of ANB020 with five of 12 patients (42 percent) achieving EASI-50, of which three patients (25%) also achieved EASI-75; ANB020 efficacy was not limited by disease severity as ANB020 was similarly efficacious in the seven of 12 enrolled patients treated with systemic immuno-modulators pre-study, which exhibited an average EASI baseline score of 36 upon enrollment, relative to the remaining five of 12 enrolled patients that did not require systemic immuno-modulators pre-study and exhibited an average EASI baseline score of 27; ANB020 was generally well-tolerated by all patients and no drug-related safety signals were observed. The most frequent adverse events reported were dizziness in 17% of patients post-placebo and headache in 25% of patients post-ANB020 administration. A single serious adverse event of depression was reported on Day 140 post-ANB020 administration, which was consistent with the patient's pre-trial history of depression and was deemed not drug-related. During the first half of 2018, AnaptysBio plans to initiate a Phase 2b randomized, double-blinded, placebo-controlled clinical trial in 200-300 adult patients with moderate-to-severe atopic dermatitis to evaluate various dose levels and dosing frequencies of subcutaneously-administered ANB020, with data expected in 2019.

  • 03

    May

ANAB AnaptysBio
$126.45

6.59 (5.50%)

12/18/17
RBCM
12/18/17
NO CHANGE
Target $108
RBCM
Outperform
AnaptysBio price target raised to $108 from $79 at RBC Capital
RBC Capital analyst Kennen MacKay raised his price target on AnaptysBio to $108 and kept his Outperform rating, citing potential from the company's Phase 2 peanut allergy dataset in Q1 of 2018 as well as its ANB019/ANB020 antibody platform.
01/19/18
BARD
01/19/18
NO CHANGE
Target $144
BARD
Outperform
AnaptysBio price target raised to $144 from $81 at Baird
Baird analyst Neena Bitritto-Garg raised her price target on AnaptysBio to $144 from $81 as the company plans to report top-line data from its ongoing Phase 2 study of its peanut allergy drug candidate. The analyst sees expectations building for the company as the drug represent a significant upside opportunity. Bitritto-Gard reiterated her Buy rating on AnaptysBio shares.
01/23/18
FBCO
01/23/18
NO CHANGE
Target $135
FBCO
Outperform
AnaptysBio price target raised to $135 from $85 at Credit Suisse
Credit Suisse analyst Alethia Young raised her price target for AnaptysBio to $135 saying she sees "room for upside" given the company's "many catalysts" in the next 12-18 months. The analyst lists the ANB-020 peanut allergy data in Q1, asthma data in Q2 and additional atopic dermatitis data potentially to be presented at a medical meeting in February as the key near-term catalysts. Young increased her probability of success estimate for ANB-019 on generalized pustular psoriasis from 0% to 25% ahead of getting first patient data potentially in late 2018 or early 2019 and raised her probability of success on ANB-020 in peanut allergy from 10% to 25% ahead of upcoming proof of concept data. She continues to like the pipeline story and keeps an Outperform rating on shares of AnaptysBio.
02/15/18
RHCO
02/15/18
NO CHANGE
Target $162
RHCO
Buy
AnaptysBio price target raised to $162 from $115 at SunTrust
SunTrust analyst Yatin Suneja raised his price target on AnaptysBio to $162 and kept his Buy rating following his conversations with the company CEO and CFO. Suneja notes that the management commentary is consistent in expectation of a trend toward tolerance in the peanut trial and a "low double digit increase" in FEV1 in the asthma trial. The analyst states that his NPV analysis suggests that peanut indication alone could be worth $133/share, thus noting "highly favorable risk-reward into data readout".

TODAY'S FREE FLY STORIES

ACN

Accenture

$166.47

-0.47 (-0.28%)

, EADSY

Airbus

$0.00

(0.00%)

04:55
07/21/18
07/21
04:55
07/21/18
04:55
Conference/Events
Farnborough International to hold an airshow »

Farnborough International…

ACN

Accenture

$166.47

-0.47 (-0.28%)

EADSY

Airbus

$0.00

(0.00%)

ATI

Allegheny Technologies

$26.65

0.08 (0.30%)

BAESY

BAE Systems

$0.00

(0.00%)

BDRBF

Bombardier

$0.00

(0.00%)

CAE

CAE

$20.96

0.17 (0.82%)

CW

Curtiss-Wright

$125.79

-0.12 (-0.10%)

DASTY

Dassault Systemes

$0.00

(0.00%)

ESLT

Elbit Systems

$118.98

0.64 (0.54%)

LMT

Lockheed Martin

$322.76

3.09 (0.97%)

BA

Boeing

$354.92

-0.57 (-0.16%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jul

  • 24

    Jul

  • 25

    Jul

  • 26

    Jul

  • 30

    Jul

  • 02

    Aug

  • 06

    Aug

  • 16

    Aug

FNWB

First Northwest Bancorp

$16.11

0.36 (2.29%)

17:48
07/20/18
07/20
17:48
07/20/18
17:48
Hot Stocks
First Northwest Bancorp names Terry Anderson chief credit officer »

First Northwest Bancorp…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FCX

Freeport McMoRan

$15.75

-0.05 (-0.32%)

17:42
07/20/18
07/20
17:42
07/20/18
17:42
Hot Stocks
Freeport McMoRan CAO Michael Arnold to retire »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

XLE

Energy Select Sector SPDR

$74.87

-0.24 (-0.32%)

, XLU

Utilities SPDR

$52.28

-0.39 (-0.74%)

17:39
07/20/18
07/20
17:39
07/20/18
17:39
General news
Week ending ETF Scorecard: Financials lead, Energy slumps »

S&P500 SECTORS:…

XLE

Energy Select Sector SPDR

$74.87

-0.24 (-0.32%)

XLU

Utilities SPDR

$52.28

-0.39 (-0.74%)

IYR

DJ US Real Estate Index Fund

$80.23

-0.68 (-0.84%)

XLP

Consumer Staples Sector SPDR

$52.84

0.3 (0.57%)

XLY

Consumer Discretionary Sector SPDR

$112.15

-0.47 (-0.42%)

XLB

S&P Select Materials SPDR

$58.31

-0.21 (-0.36%)

XLF

Financial Select Sector

$27.57

0.065 (0.24%)

XLV

Health Care Select Sector SPDR

$86.74

-0.17 (-0.20%)

XLK

Technology Select Sector SPDR

$72.55

0.01 (0.01%)

XLI

Industrial Select Sector SPDR

$74.44

-0.09 (-0.12%)

GLD

SPDR Gold Trust

$116.56

0.74 (0.64%)

SLV

iShares Silver Trust

$14.59

0.18 (1.25%)

USO

United States Oil Fund

$14.15

0.025 (0.18%)

UNG

United States Natural Gas Fund

$22.38

-0.06 (-0.27%)

HYG

iShares iBoxx $ High Yield Corporate Bond

$85.62

0.03 (0.04%)

LQD

iShares iBoxx $ Investment Grade Corporate Bond

$115.27

-0.335 (-0.29%)

TLT

iShares 20+ Year Treasury Bond Fund

$120.78

-1.46 (-1.19%)

IEF

iShares 7-10 Year Treasury Bond ETF

$102.21

-0.35 (-0.34%)

SHY

iShares 1-3 Year Treasury Bond

$83.26

-0.005 (-0.01%)

IWD

iShares Russell 1000 Value

$123.07

-0.2897 (-0.23%)

IWF

iShares Russell 1000 Growth

$149.41

-0.04 (-0.03%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

XRX

Xerox

$25.10

-0.095 (-0.38%)

, FUJIY

Fujifilm

$0.00

(0.00%)

17:25
07/20/18
07/20
17:25
07/20/18
17:25
Hot Stocks
Xerox, Centerview settle matters related to proposed Fuji tie-up »

On July 20, 2018, Xerox…

XRX

Xerox

$25.10

-0.095 (-0.38%)

FUJIY

Fujifilm

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jul

STON

StoneMor Partners

$3.61

-0.015 (-0.41%)

17:15
07/20/18
07/20
17:15
07/20/18
17:15
Hot Stocks
Breaking Hot Stocks news story on StoneMor Partners »

Oaktree Capital reports…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TEF

Telefonica

$8.70

0.07 (0.81%)

17:11
07/20/18
07/20
17:11
07/20/18
17:11
Downgrade
Telefonica rating change at Goldman Sachs »

Telefonica downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SPY

SPDR S&P 500 ETF Trust

$279.71

-0.24 (-0.09%)

, USO

United States Oil Fund

$14.15

0.025 (0.18%)

17:04
07/20/18
07/20
17:04
07/20/18
17:04
General news
Weekly CFTC Commitment of Traders highlights »

S&P500 net long 5.5K…

SPY

SPDR S&P 500 ETF Trust

$279.71

-0.24 (-0.09%)

USO

United States Oil Fund

$14.15

0.025 (0.18%)

GLD

SPDR Gold Trust

$116.56

0.74 (0.64%)

FXE

Euro Currency Trust

$112.46

0.83 (0.74%)

FXC

CurrencyShares Canadian Dollar Trust

$75.17

0.81 (1.09%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CZWI

Citizens Community Bancorp

$14.15

(0.00%)

17:02
07/20/18
07/20
17:02
07/20/18
17:02
Syndicate
Breaking Syndicate news story on Citizens Community Bancorp »

Citizens Community…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PKD

Parker Drilling

$0.30

-0.0044 (-1.46%)

17:01
07/20/18
07/20
17:01
07/20/18
17:01
Hot Stocks
Breaking Hot Stocks news story on Parker Drilling »

Whitebox Advisors reports…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Aug

RSLS

ReShape Lifesciences

$1.47

-0.02 (-1.34%)

17:00
07/20/18
07/20
17:00
07/20/18
17:00
Hot Stocks
Breaking Hot Stocks news story on ReShape Lifesciences  »

Intracoastal Capital…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BOX

Box

$26.13

-0.26 (-0.99%)

16:57
07/20/18
07/20
16:57
07/20/18
16:57
Initiation
Box initiated at First Analysis »

Box initiated with an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ALDX

Aldeyra

$7.95

-0.15 (-1.85%)

16:53
07/20/18
07/20
16:53
07/20/18
16:53
Syndicate
Breaking Syndicate news story on Aldeyra »

Aldeyra files $250M mixed…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GLRE

Greenlight Capital Re

$14.00

-0.15 (-1.06%)

16:46
07/20/18
07/20
16:46
07/20/18
16:46
Hot Stocks
Greenlight Capital Re announces departure of COO »

Greenlight Capital Ry…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RVI

Retail Value

$34.56

0.2 (0.58%)

16:38
07/20/18
07/20
16:38
07/20/18
16:38
Hot Stocks
Breaking Hot Stocks news story on Retail Value »

Luxor Capital reports…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LECO

Lincoln Electric

$92.26

0.64 (0.70%)

, ROK

Rockwell Automation

$171.32

-0.71 (-0.41%)

16:35
07/20/18
07/20
16:35
07/20/18
16:35
Hot Stocks
Lincoln Electric expands board to 11 directors, appoints Patrick Goris to board »

Lincoln Electric (LECO)…

LECO

Lincoln Electric

$92.26

0.64 (0.70%)

ROK

Rockwell Automation

$171.32

-0.71 (-0.41%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jul

  • 25

    Jul

KMX

CarMax

$77.15

-0.57 (-0.73%)

16:33
07/20/18
07/20
16:33
07/20/18
16:33
Hot Stocks
CarMax chairman sells 37,500 common shares »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LOW

Lowe's

$100.65

-0.74 (-0.73%)

16:31
07/20/18
07/20
16:31
07/20/18
16:31
Hot Stocks
Lowe's names Joseph McFarland as EVP of stores »

Lowe's Companies…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

16:30
07/20/18
07/20
16:30
07/20/18
16:30
Options
Preliminary option volume of 20.2M today »

Preliminary option volume…

PFE

Pfizer

$37.33

-0.03 (-0.08%)

16:26
07/20/18
07/20
16:26
07/20/18
16:26
Hot Stocks
FDA approves Pfizer's Biosimilar NIVESTYM for all indications »

Pfizer announced that the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Aug

  • 10

    Sep

JCP

J.C. Penney

$2.50

-0.065 (-2.53%)

16:23
07/20/18
07/20
16:23
07/20/18
16:23
Hot Stocks
J.C. Penney chief customer officer McFarland to leave company »

According to a regulatory…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VIX

Volatility Index S&P 500 Options

$0.00

(0.00%)

16:20
07/20/18
07/20
16:20
07/20/18
16:20
Options
Closing CBOE SPX and VIX Index summary for July 20th »

The CBOE Volatility Index…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ASFI

Asta Funding

$3.15

-0.1 (-3.08%)

16:18
07/20/18
07/20
16:18
07/20/18
16:18
Hot Stocks
Asta Funding receives Nasdaq non-compliance letter »

Asta Funding announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

16:17
07/20/18
07/20
16:17
07/20/18
16:17
Technical Analysis
NASDAQ market internals summary »

Volume was average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

$0.00

(0.00%)

16:16
07/20/18
07/20
16:16
07/20/18
16:16
Technical Analysis
NYSE market internals summary »

Volume was average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.